Abstract

BACKGROUND: This study aimed to undertake an analysis of ten years of real-world evidence (RWE) on overall survival (OS) following treatment of advanced gastrointestinal stromal tumor (GIST) with imatinib, sunitinib, and sorafenib using data from the Polish National Health Fund.

MATERIAL AND METHODS: Data from the Polish National Health Fund, the sole Polish public payer, identified 1,641 patients with advanced GIST who were treated with imatinib (n=1047), sunitinib (n=457), and sorafenib (n=137). The differences in overall survival (OS) were analyzed.

RESULTS: For patients with advanced GIST, the median follow-up time for patients treated with imatinib was 71 months (95% CI, 64.8–79.2), the median OS was 56.9 months (95% CI, 50.4–61.2), with survival at 12 months (89.5%), 24 months (77.9%), 36 months (66.9%), and 60 months (48.4%). The median follow-up time for patients treated with sunitinib was 41.4 months (95% CI, 34.6–49.3), the median OS was 22.8 months (95% CI, 19.2–26.8), with survival at 12 months (68.2%), 24 months (47.1%), and 36 months (31%). The median follow-up time for patients treated with sorafenib was 17.4 months (95% CI, 14.6–22.9), the median OS was 16.9 months (95% CI, 13.7–24.3), with survival at 12 months (61.9%), at 24 months (36.2%), and at 36 months (16.8%).

CONCLUSIONS: Real-world data collected in a ten-year period confirmed the effectiveness of the use of imatinib, sunitinib, or sorafenib for the treatment of advanced GIST and was comparable with the findings from clinical trials.

Keywords: Abdominal Neoplasms, Population Control, Single-Payer System, Aged, Benzamides, Disease-Free Survival, gastrointestinal stromal tumors, imatinib mesylate, Indoles, Middle Aged, Poland, Protein Kinase Inhibitors, Public Health Practice, Pyrroles, sorafenib, Sunitinib, Treatment Outcome